DVA — DaVita Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $191.35
- YTD price return
- +68.43%
- YTD total return
- +68.43%
- Market cap
- 12B
- Enterprise value
- 25.3B
- Shares outstanding
- 62.9M
- 52W low
- $101.00
- 52W high
- $247.49
- From 52W high
- -22.68%
- From 52W low
- +89.46%
- 52W range
- 62%$101–$247
- Beta
- 0.86
Volume
- Rel volume
- 0.81×
- 30D volume
- 741.2K
- 30D $ vol
- 136M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$69.0M
- Insider net 3M
- −$69.0M
- Insider net 1Y
- −$523.4M
Form 4 transactions by trade date, as filed; latest on file 2026-10-27.
Fundamentals
- Sales (ttm)
- 14.2B
- Sales/share
- $225.24
- EPS (ttm)
- $13.55
- FCF (ttm)
- 1.3B
- FCF/share
- $20.57
- Book value/share
- -$9.40
- Net margin
- 6.49%
- ROA
- 5.16%
- Current ratio
- 1.41
Growth (CAGR, ttm) · 10Y
- Sales
- +6.38%+5.95%+4.12%+2.91%
- Net income
- +19.21%+14.74%-0.94%+2.54%
- FCF
- +0.11%-0.53%+1.36%+1.66%
- Shares
- -10.91%-11.68%-9.20%-10.81%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +38.77%+27.39%+9.54%+14.63%
- Sales/share
- +19.42%+19.96%+14.66%+15.56%
- FCF/share
- +12.37%+12.62%+11.63%+13.98%
- Price
- +57.50%+34.31%+11.83%+12.55%
- Total return
- +57.50%+34.31%+11.83%+12.55%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 14.1×
- P/OI (ttm)
- 5.7×
- Fwd P/E
- 11.3×
- P/S (ttm)
- 0.8×
- P/B (mrq)
- -20.4×
- P/FCF (ttm)
- 9.3×
- EV/EBITDA (fy)
- 9.0×
- EV/Sales (ttm)
- 1.8×
- FCF yield (ttm)
- 10.75%
- Buyback yield (realized, 1y)
- 10.91%
- Shareholder yield (realized, 1y)
- 10.91%
- Buyback yield (cash, ttm)
- 9.96%
- Shareholder yield (cash, ttm)
- 9.96%
Vs own 10Y history
- P/E
- 39th
- P/OI
- 36th
- P/S
- 47th
- P/B
- 98th
- P/FCF
- 60th
Bar = where today’s multiple sits in DVA’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +3.8%10Y CAGR +6.0%YoY −1.3%EPS (diluted)
5Y CAGR +9.3%10Y CAGR +22.9%YoY +66.7%Free cash flow
5Y CAGR +0.1%10Y CAGR +4.4%YoY −46.8%TTM: operating cash flow $1.9B, capex −$576.8M
Q3 2026: operating cash flow $518.8M, capex −$159.5M
Shares (diluted)
5Y −38.1%10Y −64.9%YoY −11.2%Net income
5Y CAGR −0.7%10Y CAGR +10.7%YoY +48.3%About DaVita#
Data provided bySource: Twelve DataDaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease. DaVita provides in-center hemodialysis, peritoneal dialysis, and home dialysis options, along with related clinical support and care coordination services. The company also operates integrated kidney care programs and offers ancillary services that support treatment management and patient care across the kidney health journey. With a large network of dialysis centers in the United States and international markets, DaVita plays a major role in delivering life-sustaining renal care and serving healthcare systems, insurers, and patients who require ongoing treatment.
Denver, CO·78,000 employees·Medical Care Facilities·davita.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS $3.82 vs $3.78 est. (+1.1%); revenue $3.58B (+5% y/y) 3.0%
- Oct 27Insider sale · BERKSHIRE HATHAWAY INC, BUFFETT WARREN E (2 filers) sold 565,543 shares for $105.5M on 2 days since Jul 31
- Aug 4Earnings · Earnings release — EPS $4.02 vs $4.01 est. (+0.3%); revenue $3.55B (+5% y/y) 17.2%
ETFs holding DVA#
30 of the 193 ETFs ChartRow carries live hold DVA. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| VBR | Vanguard Small-Cap Value ETF | 0.2% |
| XLV | Health Care Select Sector SPDR Fund | 0.1% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VHT | Vanguard Health Care ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
| SPYV | SPDR Portfolio S&P 500 Value ETF | 0.0% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
